# Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)

> **NCT04095858** · PHASE3 · TERMINATED · sponsor: **Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 11 (actual)

## Conditions studied

- Hematopoietic Stem Cell Transplantation
- Acute Graft Versus Host Disease
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Efprezimod alfa
- **DRUG:** Placebo
- **DRUG:** Methotrexate
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT04095858
- **Lead sponsor:** Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-05
- **Primary completion:** 2021-11-05
- **Final completion:** 2021-11-05
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04095858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04095858, "Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT04095858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*